NGVT · Ingevity Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $258.00M | - | $333.10M | $365.10M | $284.00M | - | $376.90M | $390.60M | $340.10M | - |
| Cost of Revenue | $141.60M | - | $199.20M | $227.20M | $170.60M | - | $247.00M | $267.40M | $240.40M | - |
| Gross Profit | $116.40M | - | $133.90M | $137.90M | $113.40M | - | $129.90M | $123.20M | $99.70M | - |
| R&D | $6.70M | - | $7.00M | $7.80M | $7.70M | - | $6.70M | $7.30M | $6.80M | - |
| SG&A | $40.70M | - | $44.10M | $44.20M | $43.10M | - | $38.70M | $41.40M | $47.20M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $22.70M | - | - | $25.60M | $24.90M | - | - | - | $29.60M | - |
| Operating Income | $30.20M | - | $62.20M | ($142.70M) | $26.80M | - | $110.20M | $101.30M | $76.90M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $6.80M | - | $21.40M | $3.80M | $6.30M | - | ($30.70M) | ($50.90M) | ($15.90M) | - |
| Net Income | $59.80M | - | $43.50M | ($146.50M) | $20.50M | - | ($107.20M) | ($283.70M) | ($56.00M) | - |
| EPS - Basic | $1.70 | - | $1.20 | ($4.02) | $0.56 | - | ($2.95) | ($7.81) | ($1.54) | - |
| EPS - Diluted | $1.66 | - | $1.18 | ($4.02) | $0.56 | - | ($2.95) | ($7.81) | ($1.54) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $95.40M | $78.10M | $83.40M | $76.90M | $71.50M | $68.00M | $135.50M | $107.40M | $88.50M | $95.90M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $203.60M | $186.00M | $193.70M | $220.30M | $245.40M | $226.80M | $261.00M | $302.00M | $325.50M | $308.80M |
| Accounts Payable | $85.00M | $92.00M | $100.90M | $101.50M | $108.30M | $94.50M | $96.50M | $142.40M | $153.10M | $158.40M |
| Current Assets | $581.80M | $454.20M | $522.20M | $536.00M | $530.00M | $493.20M | $636.80M | $685.80M | $669.20M | $658.60M |
| Total Assets | $1.65B | $1.65B | $1.83B | $1.88B | $2.06B | $2.02B | $2.21B | $2.28B | $2.57B | $2.62B |
| Current Liabilities | $409.40M | $341.30M | $411.60M | $393.10M | $264.60M | $264.10M | $360.80M | $357.80M | $351.70M | $362.90M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.61B | $1.62B | $1.70B | $1.76B | $1.82B | $1.83B | $2.00B | $1.99B | $2.00B | $1.99B |
| Stockholders' Equity | $38.90M | $29.70M | $138.10M | $120.70M | $234.60M | $195.20M | $214.50M | $284.80M | $568.20M | $631.40M |
| Retained Earnings | $464.70M | $404.90M | $489.50M | $446.00M | $592.50M | $572.00M | $555.40M | $662.60M | $946.30M | $1.00B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.00M) | - | - | - | $25.40M | - | - | - | ($12.10M) | - |
| Investing Cash Flow | $106.30M | - | - | - | ($11.50M) | - | - | - | ($16.30M) | - |
| Financing Cash Flow | ($61.80M) | - | - | - | ($11.00M) | - | - | - | $23.40M | - |
| CapEx | $10.30M | - | - | $18.10M | $10.00M | - | - | - | $16.60M | - |
| Free Cash Flow | ($12.30M) | - | - | - | $15.40M | - | - | - | ($28.70M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 45.1% | - | 40.2% | 37.8% | 39.9% | - | 34.5% | 31.5% | 29.3% | - |
| Operating margin | 11.7% | - | 18.7% | -39.1% | 9.4% | - | 29.2% | 25.9% | 22.6% | - |
| EBITDA margin | 20.5% | - | - | -32.1% | 18.2% | - | - | - | 31.3% | - |
| Net margin | 23.2% | - | 13.1% | -40.1% | 7.2% | - | -28.4% | -72.6% | -16.5% | - |
| Free cash flow margin | -4.8% | - | - | - | 5.4% | - | - | - | -8.4% | - |
| FCF / Net income | -0.21 | - | - | - | 0.75 | - | - | - | 0.51 | - |
| R&D / Revenue | 2.6% | - | 2.1% | 2.1% | 2.7% | - | 1.8% | 1.9% | 2.0% | - |
| SG&A / Revenue | 15.8% | - | 13.2% | 12.1% | 15.2% | - | 10.3% | 10.6% | 13.9% | - |
| Effective tax rate | 10.2% | - | 33.0% | - | 23.5% | - | - | - | - | - |
| Return on assets | 3.6% | - | 2.4% | -7.8% | 1.0% | - | -4.8% | -12.5% | -2.2% | - |
| Return on equity | 153.7% | - | 31.5% | -121.4% | 8.7% | - | -50.0% | -99.6% | -9.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.42 | 1.33 | 1.27 | 1.36 | 2.00 | 1.87 | 1.76 | 1.92 | 1.90 | 1.81 |
| Quick ratio | 0.92 | 0.79 | 0.80 | 0.80 | 1.08 | 1.01 | 1.04 | 1.07 | 0.98 | 0.96 |
| Cash ratio | 0.23 | 0.23 | 0.20 | 0.20 | 0.27 | 0.26 | 0.38 | 0.30 | 0.25 | 0.26 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 42.42 | 55.59 | 13.28 | 15.56 | 8.76 | 10.36 | 10.31 | 7.99 | 4.52 | 4.15 |
| Liabilities / Assets | 0.98 | 0.98 | 0.92 | 0.94 | 0.89 | 0.90 | 0.90 | 0.87 | 0.78 | 0.76 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | - | 0.18 | 0.19 | 0.14 | - | 0.17 | 0.17 | 0.13 | - |
| Inventory turnover | 0.70 | - | 1.03 | 1.03 | 0.70 | - | 0.95 | 0.89 | 0.74 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 525d | - | 355d | 354d | 525d | - | 386d | 412d | 494d | - |
| Days payable outstanding | 219d | - | 185d | 163d | 232d | - | 143d | 194d | 232d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 42.9x | - | 46.8x | - | 70.7x | - | - | - | - | - |
| P / B | 66.0x | - | 14.8x | 13.0x | 6.2x | - | 6.6x | 5.6x | 3.0x | - |
| P / S | 9.9x | - | 6.1x | 4.3x | 5.1x | - | 3.8x | 4.1x | 5.1x | - |
| EV / EBITDA | 46.7x | - | - | - | 26.7x | - | - | - | 15.4x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -9.2% | - | -11.6% | -6.5% | -16.5% | - | -15.5% | -18.9% | -13.4% | - |
| Revenue CAGR (3y) | -13.1% | - | -11.6% | -4.6% | -9.5% | - | 0.0% | 2.9% | 2.0% | - |
| Revenue CAGR (5y) | -4.2% | - | 0.1% | 6.2% | -0.3% | - | 0.9% | 2.1% | 4.2% | - |
| Gross profit growth (YoY) | 2.6% | - | 3.1% | 11.9% | 13.7% | - | 0.7% | -19.5% | -23.5% | - |
| Operating income growth (YoY) | 12.7% | - | -43.6% | - | -65.1% | - | -0.2% | -16.1% | -26.0% | - |
| Net income growth (YoY) | 191.7% | - | - | 48.4% | - | - | - | - | - | - |
| EPS growth (YoY) | 196.4% | - | - | 48.5% | - | - | - | - | - | - |
| EPS CAGR (3y) | 7.1% | - | -15.8% | - | -28.8% | - | - | - | - | - |
| EPS CAGR (5y) | 6.7% | - | -6.9% | - | -12.3% | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -42.1% | - |
| FCF CAGR (5y) | - | - | - | - | -17.7% | - | - | - | - | - |
| Book value growth (YoY) | -83.4% | -84.8% | -35.6% | -57.6% | -58.7% | -69.1% | -70.2% | -60.1% | -21.7% | -9.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.17B totalPerformance Materials$606.90M · 52.0%
Performance Chemicals$400.50M · 34.3%
Advanced Polymer Technologies Segment$160.20M · 13.7%
Product / service
$400.50M totalPavement Technologies$302.60M · 75.6%
Road Markings$97.90M · 24.4%
Geographic
$1.91B totalNorth America$665.10M · 34.9%
US$585.00M · 30.7%
Asia Pacific$298.50M · 15.7%
EMEA$158.90M · 8.3%
CN$153.10M · 8.0%
South America$45.10M · 2.4%
Peer comparison
Same SIC group: Chemicals & Allied Products
Comparing Ingevity Corp against the 5 most active filers in the same SIC group.